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A3
OUTCOME ASSESSMENT METHODOLOGY IN
PERIPHERAL ARTERIAL DISEASE
A3.1
Impetus for Outcomes Research
Although the value of lifesaving therapies is boldly
displayed in both the medical and lay press, most
medical treatment provided in the developed coun-
tries is directed toward improvement in quality of life.
. Interventions for claudication and eLI are examples of
therapies directed toward the relief of symptoms and
improvement in quality of life. The goal of all such
interventions is to reduce the adverse impact of an ill-
ness or disorder on the patient's life and improve the
patient's sense of well-being and productivity. As the
costs of health care continue to spiral upward, gov-
ernments and third-party payers are seeking to con-
tain costs by limiting reimbursement to those thera-
pies proven to be effective, either in saving lives or
improving quality of life. Ultimately, the decision to
advocate a treatment, and the decision by payers and
regulatory bodies for reimbursement involves a trade-
off between the additional costs incurred and effec-
tiveness gained by performing that treatment.'
Multiple studies have been published reporting the
experience of centres on the short and long-term
results of performing interventions for PAD.
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Unfortunately, these studies are frequently difficult to
compare and to apply directly to patient management.
This is attributable to the differences in study popula-
tions with respect to disease severity and risk factors,
differences in reporting methods such as including
versus excluding technical failures in the patency
results, and the lack of outcome data relevant to the
patient such as walking ability and quality of life.?..H5.6
In terms of the levels of evidence according to the
Sackett classification, these studies all fall in the low-
est level category V.
To permit delineation of appropriate reporting crite-
ria, theAd Hoc Committee on Reporting Standards of
the Vascular Societies established categories of vascu-
lar disease commonly seen in clinical practice.v' These
criteria have served to improve the published data
available to the vascular specialist for the diagnosis
and treatment of vascular disease and have led the
way to a standardised methodology for reporting the
results of treatment. Such standardisation of method-
ology is important not only for current therapies but
also for the assessment of new technologies and tech-
niques in this time of rapid technological proliferation.
This fact has been recognised by governmental regu-
latory agencies and payers.
To evaluate therapeutic effectiveness requires the
use of outcomes measures that assess factors that
affect patients directly (eg, physical and social func-
tioning and pain) rather than only clinical measures
(eg, laboratory test scores)," ABPls, for example, are
typically of interest to the physician because they are
measurable semi-objective outcomes of the interven-
tion performed. Ultimately, patients are not interested
in their ankle pressures or patency of their arteries but
rather how far they can walk, limb salvage, and sur-
viving any procedure performed-measures of over-
all effectiveness (Table 7). The assessment of a thera-
peutic endeavour by outcome measures and clinical
parameters can yield different results.
Table 7. Examples of outcome measures of effectiveness
A3.2
Outcome Measures of Effectiveness
The outcome after treatment of PAD should focus
on the degree of change in clinical and functional
status in relation to the pretreatment status," After
surgical and percutaneous procedures, a number of
intermediate outcomes potentially related to the
procedure are important in assessing the overall
outcome after treatment. These are, for example,
technical success of the procedure and procedural
complications, resulting in either short- or long-
term morbidity. Furthermore, for decision-making
purposes it is necessary to distinguish the long-term
and short-term effects of complications on life
expectancy, quality of life, or costs. Systemic
complications (eg, MI, stroke) generally have
important short- and long-term effects, whereas
local complications (eg, haematoma, pseudo-
aneurysm, wound infection) generally only have
short-term effects.
A 3.2.1
Technical Success
Technical success is particularly relevant to percuta-
neous interventions. Without technical success, one
cannot expect a clinically successful outcome, and
technical success is not always achieved.
Furthermore, immediately after percutaneous anglo-
plasty, some measurement is required to determine
whether further intervention is necessary during the
same procedure in the form of angioplasty with
a larger balloon or stent placement. Angiographic
definitions of technical success after angioplasty
have a poor reproducibility. A high interobserver
variability has been demonstrated between radiolo-
gists performing the procedure and an independent
reader." Furthermore, the angiographic residual
Technical success of rcvascularisation procedure
Death as a result of revascularisation procedure
Short- and long-term morbidity as a result of revascularisation procedure
Change in mean ankle-brachial indices
Survival/life expectancy
Amputation-free survival /Jlfe expectancy
Quality-adjusted survival/Iifo expectancy
Generic health status (eg, medical outcomes study short form questionnaire with 36 items [SF-36))
Disease-specific measures of funct ional status (eg, walking impairment questionnaire [WIQI, walking distance)
Valuational measures/utility assessment (eg, visual rating scale [VRSI, Health Utilities Index [HUll , European quality of life
instrument [EuroQol))
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stenosis correlates poorly with the postprocedural
intraarterial pressure gradient." Measuring pressure
gradients across a treated segment, with pharmaco-
logical vasodilatation, is currently the most widely
used measure of technical success after percuta-
neous angioplasty. Intravascular ultrasound is
potentially the most accurate method of detecting a
technical successful result in large vessels. Technical
failures should be included in the assessment of
overall outcome.
A 3.2.2
Procedural Complications
One of the main problems with determining and
reporting complications is that it can be difficult to
distinguish procedural from nonprocedural mortal-
ity and morbidity. The distinction can be very sub-
jective. Thus, by convention, 3D-day mortality and
morbidity rates should be reported. It would be
useful to define complications as any untoward
event following the procedure with either a lasting
negative effect (eg, MI, death) or requiring a change
in management (eg, extra day in hospital of obser-
vation, blood transfusion). Using this definition,
for example, minor haematomas after angioplasty
that have no consequence are not counted as a
complication. A haematoma is only counted as a
complication if the patient is observed longer,
recuperates longer, requires a blood transfusion, or
requires evacuation of the haematoma. There are
multiple proposed definitions of minor and major
complications.
A 3.2.3
Criteria for Success
The short- and long-term success rates after an
intervention depend on the definition used for sue-
cess." For example, van Andel et al lO reported far
higher than average results after iliac PTA because
they used the presence of a palpable common
femoral artery (CFA) pulse as a measure of success.
Conversely, Johnston et al," by using the criteria of
clinical improvement plus an increased ASPI,
reported lower than average results because subse-
quent occlusive events distal to the percutaneous
transluminal angioplasty (PTA) (typically superficial
femoral artery [SFA] occlusion) were wrongly
included as PTA failure. Table 8 illustrates how
patency results may vary by applying different crite-
ria of a successful outcome to the same data.
ABPI is commonly used as an objective measure
of success but may be influenced by disease, or
treatment, at other sites. Furthermore, exercise or
drug regimens that improve walking distance do
not necessarily improve ASPI or blood flow.P
The results of infrapopliteal PTA are very difficult to
ascertain because this is usually accompanied by
treatment at other sites. Furthermore, some early
reports of surgical series, when compared with
audited data, were unduly optimistic.H ,t 5 Similarly,
it is well known that results of personal or institu-
tional series are often significantly better than those
from strictly controlled and audited multicentre
trials.
Clinical success in the surgical and radiological
literature is defined as some combination of symp-
tomatic improvement and objective haemodynamic
success. After the first publication of the reporting
standards for surgical and percutaneous interven-
tions, many authors combined symptomatic criteria
and objective haemodynamic criteria with an 'or.'
This would have been classified as at least +1 level
of improvement- and implies using a very lenient
criteria for success. The revised reporting standards
recommend a more stringent success criteria (at
least +2 level of improvement), stating that both
symptomatic improvement 'and' objective haerno-
dynamic improvement are required for success." A
distinction is made between i) clinical success as
determined by symptomatic improvement 'and'
objective haemodynamic improvement of the entire
limb, ii) haemodynamic success, which applies to
objective improvement of the entire limb, and iii)
patency, which applies to the revascularised or
bypassed segment only," Furthermore, it is impor-
tant to distinguish primary, assisted primary, and
secondary patency.
Table 8: Different patency rates obtained by applying criteria of a successful outcome to exactly the same data12
Criteria used to measure successful outcome
!:> Thigh:brachial index >0.1
!:> Thigh:brachial index >0.1 plus no clinical deterioration
!:> Ankle:brachial index >0.1
!:> Ankle.brachial index >0.1 plus no clinical deterioration
!:> Ankle:brachial index plus clinical improvement
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Patency rate (%)
89
79
68
58
5-1
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Primary pateucy implies un interrupted patency fol-
low ing only the procedure being evaluated. Assisted
primary patCl/cy is used in reporting surgical inter-
ventions and implies that cases undergoing a revi-
sion of the graft before graft occlusion, that is, pro-
phylactic interventions, are not counted as failures if
the revision salvages the graft. Secondanj paieno]
implies patency following the initial procedure or
following a reintervention to restore patency of an
occluded graft or vessel. After either a surgical or
endovascular procedure, secondary patency implies
the need in some patients for reopening of the treat-
ed segment by a second intervention. (See also A
3.2.9, Patency, p S37.)
Apart from measuring symptomatic improvement,
objective improvement, and patency, outcomes
directly relevant to the patient should be measured.
Numerous instruments have been developed to
measure health-related quality of life that are useful
in this regard. A distinction should be made between
the descriptive and valuational instruments.
Whereas descriptive instruments provide scores for
quality of life on various dimensions, oaluational
measures provide a quantitative assessment of quality
of life. Descriptive instruments include generic and
disease-specific health status questionnaires. These
yield scores describing the respondent's mobility,
functioning, mental health, and overall well-being.
Yaluatlonal instruments yield holistic numerical val-
ues of the quality of life on a scale from 0.0 (usually
anchored as death) to 1.0 (usually anchored as per-
fect health). Such values are required in cost-effec-
tiveness analysis by health care purchasers when
deciding whether a particular gain in effectiveness
justifies the additional cost, for example, use of stent
placement rather than, for example, balloon angio-
plasty alone (see also A 4, Economic Aspects of PAD,
p S39).
Studies evaluating the relationship between vari-
ous outcome measures have shown moderate to poor
correlation. For example, the ABPI does not correlate
well with the degree of exercise impairment, and
changes in ABPI do not correlate well with changes
in walking distance.t- The correlation between vari-
ous health status questionnaires and walking dis-
tance or ABPI has been demonstrated to be poor to
rnoderate.F-tv'? The relationship between ABPI or
angiographic findings and quality-of-life measures
also appears to be weak.P Similarly, the relationship
between descriptive quality-of-life measures and val -
uational measures in patients with PAD appears
weak.s! These results seem to imply that "success" of
an intervention is a multidimensional entity requir-
ing consideration of traditionally used measures of
medical effectiveness (eg, ABPI, patency), walking
ability of the patient (functional status either meas-
ured directly or with the walking impairment ques-
tionnaire), descriptive health status measures (eg, SF-
36), and measures valuing quality of life (eg, HUI,
EuroQol).
Recommendation 1: Outcome measures in
p-eripheral arterial disease
In determining the baseline severity of disease and
changes in response to treatment,
the following outcomes should be documented:
• Objective/haemodynamic status of the limb
• After revascularisation: patency of the revascu-
larised segment
• Symptomatic status of the limb
• General quality of life of the patient
• Value or utility assessment of quality of life of
the patient
Outcome Measures should reflect a standardised
reporting time frame similar to that recommended by
the SVS/ISCVS for endovascular procedures:
• Initial outcome = 30 days after procedure
• Short-term = 1 to 12 months, but statistically
valid data" at least to 6 months
• Intermediate-term = 6 to 24 months, but
statistically valid data" beyond 1 year
• Long-term = statistically valid data" beyond
2 years
* Life Table or Kaplan-Meier projections with stan-
dard error not exceeding 10% at this point.
Critical Issue 1: Relationship between different
outcome measures
Methodological work is required to understand the
relationship between traditionally used measures
of medical effectiveness (eg, ABPI, patency), walk-
ing ability of the patient (eg. walking distance or
walking impairment questionnaire), descriptive
health status measures (eg, SF-36), and measures
valuing quality of life (eg, HUI, EuroQol), especial-
ly in severe ischaemia.
A 3.2.4
Objective Outcome Measures
As an objective measure of improvement, haernody-
namic criteria are commonly used. An increase in the
ABPI of more than 0.15 (as stand-alone criteria; 0.10 if
combined with symptomatic criteria) or an increase in
ABPI to more than 0.90 has been recommended as an
objective measure of success.5 If the ABPI cannot be
measured accurately, for instance, in diabetic patients,
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the toe pressure may be substituted. The term haenic-
dynamic failure indicates a lack of significant haemody-
namic improvement as determined by an increase in
ABPI, using distal pressures, regardless of whether the
artery is patent. In evaluating exercise and drug regi-
mens for claudication, however, the mean ABPI gen-
erally does not improve in spite of improvements in
exercise performance and functional status.B To
enable comparison between the results of revascular-
isation and exercise or medical treatments, every clin-
ical trial for Ie should evaluate the severity and
impact of claudication using a treadmill exercise test
(see Recommendation 43, p S113).
A 3.2.5
Symptomatic Outcome Measures
Symptom severity and outcome of an intervention can
be judged by classifying patients' symptoms on a
scale. The two most well-known classifications are the
Fontaine stages and Rutherford's categories, which is
currently recommended to determine significant clin-
ical improvement (Table 9).5 Category 0 indicates the
asymptomatic state; category I, mild; 2, moderate
claudication; and 3, severe claudication; 4, ischaemic
rest pain; 5, minor tissue loss; and 6, major tissue loss.
Objective criteria are also part of the overall published
clinical classification scheme and are based on the sub-
ject's ability to complete a treadmill exercise test.
However, the objective criteria of improvement
should probably be considered separately to avoid
confusing "symptomatic improvement" and "objec-
tive improvement." Symptomatic improvement
requires an upward shift of at least one category on
the scale except for those with actual tissue loss (cate-
gory 5) who must at least improve to a level of claudi-
cation to be considered improved.
A 3.2.6
Disease-Specific Health Status Questionnaires
Probably the oldest disease-specific questionnaire for
intermittent claudication is the one developed by
Rose.22,23 Although not very sensitive, this question-
naire has been widely used in identifying patients
with claudication.s'> The WIQ is a disease-specific
instrument developed to characterise walking ability
through a questionnaire as an alternative to treadmill
testing. This has been demonstrated to be useful in
intermittent claudication.> It includes questions
about the degree of pain, aching, or cramps, the rea-
son for the difficulty walking, walking distance,
walking speed, and stair climbing. It is proposed that
a disease-specific health status questionnaire be used
to document symptomatic status. Currently, there is
no disease-specific questionnaire for severe
ischaemia.
To assess the patient's activity level, the peripher-
al arterial disease Physical Activity Recall (PAD-
PAR) questionnaire may be used; this is a measure of
habitual physical activity and provides a global esti-
mate of the total energy expendedP A combined
generic- and disease-specific questionnaire was
developed by McDaniel et al,24 using items from sev-
eral previously developed and tested instruments,
including the instrumental activities of daily living
questionnaire. The Spitzer QL-index, which was
originally designed for application in oncology, has
also been used for measuring quality of life in
patients with PAD. 28,29
Recommendation 2: Symptomatic outcome
measures
To measure baseline and changes in symptomatic
disease-specific health status, a disease-specific
health status questionnaire should be used, such as
the Walking Impairment Questionnaire (WIQ).
Critical Issue 2: Symptomatic outcome measures in
acute and critical limb ischaemia
There is a need for a validated disease-specific
questionnaire for patients with acute or critical
limb ischaemia.
Table 9. Classification of peripheral arterial disease: Fontaine's stages and Rutherford's categories
Fontaine
Stage Clinical Grade
I Asymptomatic a
lIa Mild claudication I
lIb 1\Iodera to-severe I
claudication I
III Ischaemic rest pain II
1lI
IV Ulceration or gangrene III
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Rutherford
Category
a
1
2
3
4
5
6
Clinical
Asymptomatic
Mild claudication
Moderate claudication
Severe claudication
Ischaernic rest pain
Minor tissue loss
Major tissue loss
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A 3.2.7
Generic Health Status Questionnaires
Several generic instruments are useful in gathering
information regarding quality of life. Though some-
what different in format, each of these instruments
attempts to obtain important data in four major cat-
egories: functional status assessment, perceived
health, psychological well-being, and role function.
Functional status assessment is directed toward deter-
mining how well the patient can perform basic phys-
ical tasks, such as the ability to climb stairs, read a
newspaper, or hold a pen. Perceived health identifies
how healthy a patient believes he or she is and how
much a patient worries about his or her health.
PsycllOlogicnl toell-being focuses on the extent to
which patients become distressed, anxious, or
depressed about their illnesses and associated treat-
ments. Role function evaluation is directed toward
the assessment of the impact of a patient's disorder
on his or her ability to work and perform his or her
obligatory duties, such as care for his or her family,
and on his or her resources.
Studies evaluating health-related quality of life
have demonstrated that patients with PAD have poor-
er scores on various measures of functional health and
well-being compared with patients of similar age and
sex without the disease.2o.21 The Medical Outcomes
Study Short-Form 36 (SF-36) is a generic health status
- !
questionnaire that appears to be useful in evaluating
quality of life in patients with PAD.19,21,JO The SF-36
assesses eight health dimensions-physical function-
ing, social functioning, role limitations due to physical
problems, role limitations due to emotional problems,
pain, mental health, energy, general health percep-
tion-and a one-item question: change in health dur-
ing the past year.
For each SF-36 dimension, item scores are coded,
summed, and transformed onto a scale from 0 to 100,
with 100 being the highest score. The RAND-36
(RAND Corporation) and the SF-36 are practically the
same and have identical items, but the scoring is
slightly different for the dimensions pain and general
health perception." The dimensions physical func-
tioning and role limitations due to physical function-
ing and pain are especially affected by the presence of
PAD (Figure 19). At least 8 of the 36 questions can be
considered directly relevant for the evaluation of PAD,
including questions about walking distance, the abili-
ty to climb stairs, and pain. The SF-36 (and RAND-36)
is a generic measure that has been used in multiple
settings and validated across a wide spectrum of dis-
eases; therefore comparison with the outcomes of
patients with other diseases and comparison with the
healthy population are possible (Figure 19). Both the
RAND-36 and SF-36 have been translated into several
languages, and both can be completed by the patients,
themselves.
.. -
Figure 19:Quality of life assessed with the RAND 36-ltem Health Survey 1.0 (mean scores with confid ence intervals) in patients with periph-
eral arterial disease compared with the general population. Reproduced from Mcd Dccis Making 1996;16:217-225.
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The Functional Status Questionnaire and instrumen-
tal activities of daily living have also been applied in
the asse ssment of PAD.2~, 32TIle Sickness Impact Profile
(SIP) has been used in the assessment of PAD and in
the United States in a randomised controlled clinical
trial comparing the outcome of PTA and bypass sur-
gery for PAD.J8,33,34,35 The Nottingham Health Profile
(NHP) has been used in the United Kingdom in a
study comparing PTA with medical treatment.36,37,38
Both the SIP and NHP are fairly lengthy question-
na ires. In measuring health-related quality of life, a
number of issues, including validity, reliability, and
feasibility, need to be considered. Such criteria have
been proposed by various scientific groups
(Association for Pharmacoeconomics and Outcomes
Research [APOR], 1996; European Organisation for
Research and Treatment of Cancer [EORTCD and are
increasingly requested by guidelines (Canadian
Coordinating Office for Health Technology
Assessment [CCOHTA], 1996; Gold et al, 1996). .
TIle following criteria should be applied when
choosing a measure of health-related quality of life, in
particular for multinational clinical trials:
• Validity (the extent to which a technique measures
what it is supposed to measure)
• Reliability (stability of scores)
• Feasibility (burden for the respondent and investi-
gator)
• Responsiveness (likelihood of detecting a clinically
important change or treatment effect)
• Cultural and language adaptations (standardised
translations, linguistic evaluations, psychomo or
validations, attention to cultural issues)
Recommendation 3: Generic health status outcome
measures
Until better instruments are developed, if general
health status is to be measured, the Short Form 36
(SF-36 or RAND-36) questionnaire is recommended
to measure baseline and changes in generic health
status.
A 3.2.8
Valuing Health-Related Quality of Life and Utility
Assessment
To determine whether the additional costs incurred
by performing an intervention are justified com-
pared with the effectiveness gained, the gain in
effectiveness needs to be valued.' The recommend-
ed approach is to express effectiveness in quality-
adjusted life years (QALYs), which is a composite
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value combining both length and quality of life.' In
estimating QALYs, every year spent in full health is
counted as a full year. Years spent in less than full
health are counted as some fraction of a year, as
determined by the value of the health state. For
example, if a subject enjoys 2 years of full health
followed by 6 years in a health state with pain val-
ued at 50% of the values of full health, the patients
would have had 5 QALYs (ie, 2 + 50% of 6). Thus,
calculating QALYs requires quantifying the quality
of life in the various health states. A few studies
have determined values for various health states
related to PAD. Such holistic values reflect the rela-
tive value of life with the disease compared with
perfect health. They may be expressed, for exam-
ple, on a scale from zero to I, where zero is equiva-
lent to death and 1 equals perfect health compara-
ble to contemporaries. These measures include the
time trade-off, standard gamble, rating scale, visu-
al analog scale, EuroQol, HUI, and Quality of Well-
Being scale.39,~o.~\,~2,H,44
In the time trade-off, patients are asked to choose
between trading life expectancy to avoid morbidity
versus living longer with morbidity. In the standard
gamble, patients are asked to choose between taking
it risk of immediate death to avoid the morbidity of
less desirable health states versus the certainty of
living with morbidity. Both the time trade-off and
standard gamble determine th e patient's point of
indifference between trading life expectancy or tak-
ing risk, respectively, and liv ing with morbidity.
The rating scale and visual analog methods require
subjects to directly value health states on a scale
from zero to 100, zero generally being equivalent to
death and 100 perfect health, by either responding
with a number or placing a mark on a line.
The Health Utility Index, Quality of Well-Beil/g
Scale, and EuroQol are all multi-attribute utility
instruments that classify patients into one of many
health states determined by their responses to
questions on several dimensions (or attributes) of
health. For each health state, a value can be calcu-
lated using a known formula that reflects how
important each dimension is considered. This for-
mula was derived using multi-attribute utility the-
ory and determined by obtaining values from the
general population based on generic scenarios
describing the health state." Typically, these multi-
attribute values for claudication range from 0.60 to
0.85, from 0.30 to 0.45 for rest pain, and from 0.20 to
0.60 for amputatlon.v-" The obtained values
depend on the questionnaire used. The standard
reference gamble generally yields the highest val-
ues, followed by the time trade-off, rating or visual
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analog scale, and then the HUI. These differences
are due to attitudes toward risk, how scales are
interpreted, and whether the values are obtained
from patients or the general public.
In general, the recommended perspective for per-
forming a cost-effectiveness analysis is societal,'
implying that values for such analyses should be
obtained from the general public. Both the HUI and
the EuroQol provide known societal values for
generic health states, implying that one only needs
to determine the patients' generic health states. In
general, the HUI is recommended for obtaining val-
ues from the societal perspective. The EuroQoL can
provide similar values with fewer questions and is
easier to administer but discriminates less 'well
between health states, is less sensitive to changes,
and is not based on standard reference gamble util-
ities.~6 Alternatively, disease-specific scenarios of
health states can be formulated based on the
patients' experiences and a general population
asked to value these scenarios, which for amputa-
tion especially yielded lower values than when the
scenario was based on generic scenariosY
Recommendation 4: Value/utility assessment
Valuing health-related quality of life is only neces-
sary in the setting of a clinical trial with a cost-
effectiveness study. The Health Utilities Index or
EuroQol are recommended to obtain a single glob-
al value from the societal perspective based on the
health status of the patient group under considera-
tion. In daily clinical practice, one verbal rating
scale question, or a visual analog scale question,
can be used to obtain a global value for quality of
life from the patient's perspective.
A 3.2.9
Patency
Determining patency is required for presentation of
the results of percutaneous and surgical interventions
in scientific journals. Patency should always be based
on objective findings and should be distinguished
from symptomatic and objective improvement as
already defined. Whereas symptomatic and objective
improvement both apply to the entire limb, patency
applies to the revascularised or bypassed segment
only. For patency, anyone of five criteria must be met,
of which the following two are the most relevant>
• Demonstrably patent by vascular imaging using
angiography, (colour-guided) Duplex ultrasound or
magnetic resonance angiography
• Maintenance of achieved im provemen t in the
appropriate segmental limb pressure index; that is,
not more than 0.10 below the highest postoperative
index. If a drop of more than 0.10 is measured,
imaging proof of patency is required. The most
appropriate pressure index is the one at the next
level beyond the revascularised segment or distal
anastomosis.
A graftor revascularised segment is considered to
have "primary" patency if it has had uninterrupted
patency with either no procedure performed on it or a
procedure (eg, transluminal dilation or a proximal or
distal extension to a graft) to deal with disease pro-
gression ill the adjacent natioc vessel. Thus, the only
exceptions that do not disqualify the graft for primary
patency are procedures performed for disease befond
the graft or the revascularised segment. Dilation or
minor revisions performed for stenoses, dilation, or
other structural defects, or closing missed arterio-
venous (AV) fistulas in an in situ vein bypass, before
occlusion, do not constitute exceptions, because they
are intended to prevent eventual failure of the revas-
cularization procedure.
The additional designation of "assisted primary
patency" applies to the special situation in which
patency was never lost but rather maintained by pro-
phylactic intervention. If patency of the revascularised
segment is restored afterocclusion, by thrombectomy,
thrombolysis, or transluminal angioplasty, or if any
problems with the revascularised segment itself, for
example, the graft or one of its anastomoses, require
revision or reconstruction, all must be listed under
"secondary" patency. In the case of a graft, a "redo" or
secondary reconstruction does not contribute to sec-
ondary patency, unless most of tile original graft and at
least aile anastomosis are retained ill continuinj.Although
the above definitions were originally developed for
bypass grafts, they now can be equally applied to any
type of revascularised segment, such as endarterecto-
my, PTA, or stenting, but it is generally agreed that the
entire anatomic arterial segment should be considered
as one, much like a bypass graft.
Recommendation 5: Definition of patency
Vascular imaging is the reference standard for
determining patency. In its absence, patency may
be defined as maintenance of achieved haernody-
narnic improvement in the relevant segment; ie, not
more than 0.10 below the highest postoperative
index. If a drop of more than 0.10 is measured,
proof of patency with vascular imaging is required.
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A4
ECONOMIC ASPECTS OF PERIPHERAL
ARTERIAL DISEASE
The general purpose of an economic evaluation in the
field of health care is to relate the costs of a diagnostic
or therapeutic strategy to its outcomes. The two com-
ponents of the evaluation are thus a measure of effec-
tiveness and an estimate of costs . Economic evaluation
is currently both a decision tool and an evolving aca-
demic discipline.P Thus, existing guidelines reflect the
current state of the art but are subject to alterations
when new methodological tools become available.v'>
The following discussion and recommendations relate
to the interpretation and design of specialised expert
studies aimed at identifying, as accurately as possible,
the economic implications of medical procedures. It is
of course not intended that these detailed considera-
tions necessarily apply to all clinical studies.
A4.1
Perspective in Economics
The fundamental principle is that the figure chosen to
estimate the cost of given goods or a service will
depend on the viewpoint chosen; there is no "right"
figure, but rather calculations must be made consis-
tently. From the viewpoint of the patient, relevant
costs are all of the out-of-pocket expenses. This
includes, for instance, nonreimbursed medical fees
and drug costs plus non-health care costs such as
extra help in the household or alterations for an
amputee that are not covered by insurance or social
benefits. From the viewpoint of the hospital, person-
nel, equipment, supplies, capital, and overhead in the
hospital are relevant. The chosen viewpoint can affect
the results profoundly. For example, the mean costs of
treating a severe contrast reaction were found to be
$15 (Euro 14) from the perspective of the radiology
department, $910 (Euro 846) from the perspective of
the hospital, and $3,103 (Euro 2,886) for the third-
party payer. 6 Simil arly, the chairman of a medical,
surgical, or technical department is usually account-
able for personnel, equipment, maintenance, and sup-
plies in his or her own department but may not con-
sider costs borne by other departments.' The health
care system consider all medical costs but not social
costs, and the insurer will consider total payment
made to health care provlders.v' The most encompass-
ing viewpoint is society's and is recommended in cur-
rent guidelines, although it involves an exhaustive
data collection.
Recommendation 6: Perspective in economic evalu-
ation of peripheral arterial disease
It is important to collect cost and outcome data
related to the diagnosis and treatment of peripheral
arterial disease. Current guidelines recommend
that the overall societal perspective be taken to
compute the costs and effectiveness.
A4.2
General Principles of Economic Evaluation
Economic evaluation from the societal viewpoint
requires the following:
• The time horizon for the computation of costs and
benefits must be defined: that is, the time over
which the consequences of the strategy are likely to
extend.
• The case-type or the population chosen for the
assessment of costs and benefits must be defined:
the cost of a procedure will depend, for instance, on
the severity of the underlying disease or the frailty
of the patient. When economic analysis is under-
taken alongside clinical trials, costs data are usual-
ly collected on all of the patients included. An eco-
nomic evaluation performed retrospectively or
with a model requires decisions about which
patients' data will be used to derive costs and ben-
efits.
• The type of health care facility must be defined: the
costs are different from one facility to another (and
from one country to another). Factors of variation -
include the type of equipment, the quality of main-
tenance, the number of patients and the ability of
the operators. Optimally, economic assessment
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